Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 79

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 5
Chunk 79
---
                                                             (2.15                      (1.85                 (0.64       (0.76  

                                                               Three months ended                                                                        
  (in thousands of US dollars, except for per share data)      December                            September                 June                        
                                                               31,                                 30,                       30,                         
                                                                                                                                                         
                                                               2023                                2023                      2023                        
                                                               $                                   $                         $                           
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Revenues                                                                              1,213                     1,952                1,392      2,585  
  Net (loss) / profit                                                                  (1,565                      (776                 (860       (285  
  Net (loss) / profit per                                                               (0.85                     (0.42                (0.47      (0.15  

  (1)      Net                                                                                                                                 

Historical
quarterly results of operations and net loss cannot be taken as reflective of recurring revenue or expenditure patterns of predictable
trends, largely given the non-recurring nature of certain components of our revenues, unpredictable quarterly variations in net finance
income and of foreign exchange gains and losses.

Historical
quarterly sales and results primarily fluctuate due to variations in the timing of customer orders of different product mixes, and changes
in the optimal use of our capacity to manufacture products.

Consolidated
Statements of Financial Position Data

  (in thousands of US dollars)                                                                
 ──────────────────────────────────────────────────────────────────────────────────────────────
  Cash and cash equivalents                                   16,393       6,678      10,190  
  Trade and other receivables and other assets                 4,897       1,398       2,915  
  Inventory                                                    2,691       4,009       2,772  
  Restricted cash equivalents                                    123           8           -  
  Property, equipment and intangible assets                   10,966      11,652      11,963  
  Total assets                                                35,070      23,745      27,840  
  Payables, accrued liabilities and income taxes payable       4,835       1,012       1,276  
  Current portion of provisions                                  385           -           -  
  Current portion of deferred revenues                           120           -           -  
  Lease liabilities                                            2,310       1,698       1,